Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia

OBJECTIVES: Ceftolozane/tazobactam is approved for hospital-acquired/ventilator-associated bacterial pneumonia at double the dose (i.e. 2 g/1 g) recommended for other indications. We evaluated the bronchopulmonary pharmacokinetic/pharmacodynamic profile of this 3 g ceftolozane/tazobactam regimen in...

Descripción completa

Detalles Bibliográficos
Autores principales: Caro, Luzelena, Nicolau, David P, De Waele, Jan J, Kuti, Joseph L, Larson, Kajal B, Gadzicki, Elaine, Yu, Brian, Zeng, Zhen, Adedoyin, Adedayo, Rhee, Elizabeth G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225904/
https://www.ncbi.nlm.nih.gov/pubmed/32211756
http://dx.doi.org/10.1093/jac/dkaa049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225904/
https://www.ncbi.nlm.nih.gov/pubmed/32211756
http://dx.doi.org/10.1093/jac/dkaa049

Ejemplares similares